Mixed trend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Dec 26 · inside the Ichimoku cloud · RSI 0 (oversold) · MACD above its signal · at its 52-week low
None of the 29 investors followed here reported a position in BRAXF in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a BRAXF trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for BRAXF.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | ||
| 2025 | 20.0 | -16.7 | -40.0 | 33.3 | 6.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -92.2 | −93.3% |
| 2024 | 27.4 | 26.8 | -7.9 | -21.9 | 12.0 | -10.7 | -60.0 | 0.0 | -5.0 | 42.1 | 29.6 | -57.1 | −65.1% |
| 2023 | 175.7 | -9.8 | -58.5 | -16.8 | 8.2 | 4.1 | -24.9 | -30.9 | 7.5 | -26.0 | -8.1 | -36.8 | −76.8% |
| 2022 | -20.4 | -2.5 | 1.9 | -9.4 | -1.1 | 3.5 | -5.6 | 35.7 | -32.5 | -2.8 | -17.1 | -40.3 | −69.5% |
| 2021 | -2.8 | -13.3 | -26.9 | 24.4 | -31.3 | -23.7 | -3.9 | -16.9 | -16.0 | -12.3 | -35.2 | -35.9 | −90.2% |
| 2020 | 56.7 | 108.6 | -51.5 | -35.4 | -14.3 | 15.1 | -16.0 | 32.2 | 34.1 | +50.5% |
No analyst coverage for this instrument.
Braxia Scientific Corp. operates as a medical research company with clinics that provide ketamine treatments for persons with depression and related disorders. The company also owns and operates multidisciplinary clinics that offers treatment of mental health disorders. In addition, it is involved in the research activities related to discovering and commercializing novel drugs and delivery methods; and development and acquisition of derivatives of ketamine and psilocybin, as well as other psychedelic products from its IP development platform. The company is headquartered in Mississauga, Canada.
No recent headlines.